What happens when you stop using Wegovy?

Health & LifestyleNews
156

Listen to article (english)

Translate to Spanish or other 102 languages!

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used for weight loss and weight management and to reduce the risk of major cardiovascular events. Image for illustration purposes
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used for weight loss and weight management and to reduce the risk of major cardiovascular events. Image for illustration purposes

Mega Doctor News

- Advertisement -

Medical News Today

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used for weight loss and weight management and to reduce the risk of major cardiovascular events. The Wegovy injection is also approved to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults.

Wegovy is available as a weekly injection and a once-daily tablet.

- Advertisement -

Stopping Wegovy, especially suddenly, can affect a person’s body and condition management goals. A person should always talk with their prescribing doctor before stopping Wegovy or any prescription medication.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/drugs-what-happens-when-you-stop-taking-wegovy?utm_term=feedcontent&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2026-02-24&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

Information source: https://www.medicalnewstoday.com

- Advertisement -

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Heart Disease in Women: The Myths Putting Lives at Risk
Next article
How UTIs Trigger Delirium and Speed Cognitive Decline in Older Adults

More Articles

STHS to Host Annual Think Pink Parade to Drive Breast Cancer Awareness, Oct. 3rd

Breast cancer remains one of the most commonly diagnosed cancers among women in the United States and is a leading cause of cancer-related deaths.

DHR Health Enhances Ear, Nose, and Throat Care with Addition of Dr. Tess Hill

As part of its ongoing commitment to expanding access to outstanding healthcare throughout the Rio Grande Valley, DHR Health is pleased to welcome Dr. Tess Hill to its growing team of physicians. Dr. Hill joins DHR Health as an otolaryngologist (ear, nose and throat physician) and looks forward to providing compassionate, patient-centered care.

Accelerator Program Relaunches Oct. 15 with Expanded Focus on AI and Healthcare

AltaCair Foundation, in partnership with Genentech as the 2026 co-host, will host its fourth annual Accelerator summit on Thursday, October 15, 2026, from 8:00 a.m. to 12:00 p.m. at the Harlingen Convention Center.

Scientists Discover Key Biological Link Between Endometriosis and Chronic Pain

New Yale research may help explain why some patients with a small number of growths experience debilitating pain, while others with more widespread disease do not have symptoms.
- Advertisement -